Martinus J van Amerongen1, Sjoerd F M Jenniskens2, Peter B van den Boezem3, Jurgen J Fütterer4, Johannes H W de Wilt3. 1. Department of Radiology and Nuclear Medicine, Radboud University Nijmegen Medical Center, The Netherlands. Electronic address: Martin.vanAmerongen@radboudumc.nl. 2. Department of Radiology and Nuclear Medicine, Radboud University Nijmegen Medical Center, The Netherlands. 3. Department of Surgery, Radboud University Nijmegen Medical Center, The Netherlands. 4. Department of Radiology and Nuclear Medicine, Radboud University Nijmegen Medical Center, The Netherlands; MIRA Institute for Biomedical Engineering and Technical Medicine, University of Twente, The Netherlands.
Abstract
BACKGROUND: Hepatic resection and ablative treatments, such as RFA are available treatment options for liver tumors. Advantages and disadvantages of these treatment options in patients with colorectal liver metastases need further evaluation. The purpose of this study was to systematically evaluate the role of radiofrequency ablation (RFA) compared to surgery in the curative treatment of patients with colorectal liver metastases (CRLM). METHODS: A systematic search was performed from MEDLINE, EMBASE and the Cochrane Library for studies directly comparing RFA with resection for CRLM, after which variables were evaluated. RESULTS: RFA had significantly lower complication rates (OR = 0.44, 95% CI = 0.26-0.75, P = 0.002) compared to resection. However, RFA showed a higher rate of any recurrence (OR = 1.66, 95% CI = 1.15-2.40, P = 0.007), local recurrence (OR = 9.56, 95% CI = 6.85-13.35, P = 0.001), intrahepatic recurrence (OR = 1.96, 95% CI = 1.34-2.87, P = 0.001) and extrahepatic recurrence (OR = 1.21, 95% CI = 0.90-1.63, P = 0.22). Also, 5-year disease-free survival (OR = 2.20, 95% CI = 1.28-3.79, P = 0.005) and overall survival (OR = 2.35, 95% CI = 1.49-3.69, P = 0.001) were significantly lower in patients treated with RFA. CONCLUSIONS: RFA showed a significantly lower rate of complications, but also a lower survival and a higher rate of recurrence as compared to surgical resection. All the included studies were subject to possible patient selection bias and therefore randomized clinical trials are needed to accurately evaluate these treatment modalities.
BACKGROUND: Hepatic resection and ablative treatments, such as RFA are available treatment options for liver tumors. Advantages and disadvantages of these treatment options in patients with colorectal liver metastases need further evaluation. The purpose of this study was to systematically evaluate the role of radiofrequency ablation (RFA) compared to surgery in the curative treatment of patients with colorectal liver metastases (CRLM). METHODS: A systematic search was performed from MEDLINE, EMBASE and the Cochrane Library for studies directly comparing RFA with resection for CRLM, after which variables were evaluated. RESULTS: RFA had significantly lower complication rates (OR = 0.44, 95% CI = 0.26-0.75, P = 0.002) compared to resection. However, RFA showed a higher rate of any recurrence (OR = 1.66, 95% CI = 1.15-2.40, P = 0.007), local recurrence (OR = 9.56, 95% CI = 6.85-13.35, P = 0.001), intrahepatic recurrence (OR = 1.96, 95% CI = 1.34-2.87, P = 0.001) and extrahepatic recurrence (OR = 1.21, 95% CI = 0.90-1.63, P = 0.22). Also, 5-year disease-free survival (OR = 2.20, 95% CI = 1.28-3.79, P = 0.005) and overall survival (OR = 2.35, 95% CI = 1.49-3.69, P = 0.001) were significantly lower in patients treated with RFA. CONCLUSIONS: RFA showed a significantly lower rate of complications, but also a lower survival and a higher rate of recurrence as compared to surgical resection. All the included studies were subject to possible patient selection bias and therefore randomized clinical trials are needed to accurately evaluate these treatment modalities.
Authors: Elena A Kaye; Francois H Cornelis; Elena N Petre; Neelam Tyagi; Waleed Shady; Weiji Shi; Zhigang Zhang; Stephen B Solomon; Constantinos T Sofocleous; Jeremy C Durack Journal: Eur Radiol Date: 2018-11-06 Impact factor: 5.315
Authors: Kurinchi Gurusamy; Neil Corrigan; Julie Croft; Maureen Twiddy; Stephen Morris; Nick Woodward; Steve Bandula; Daniel Hochhauser; Vicky Napp; Alison Pullan; Nicholas Jakowiw; Raj Prasad; Steven Olde Damink; C J H M van Laarhoven; Johannes H W de Wilt; Julia Brown; Brian R Davidson Journal: Trials Date: 2018-02-13 Impact factor: 2.279
Authors: Marie Beermann; Johan Lindeberg; Jennie Engstrand; Karolina Galmén; Silja Karlgren; David Stillström; Henrik Nilsson; Piotr Harbut; Jacob Freedman Journal: Eur J Radiol Open Date: 2018-12-05
Authors: Sebastian Stintzing; Jobst von Einem; Christoph Fueweger; Alfred Haidenberger; Michael Fedorov; Alexander Muavcevic Journal: Cancer Res Treat Date: 2018-04-16 Impact factor: 4.679
Authors: Emilio De Raffele; Mariateresa Mirarchi; Dajana Cuicchi; Ferdinando Lecce; Claudio Ricci; Riccardo Casadei; Bruno Cola; Francesco Minni Journal: World J Gastrointest Oncol Date: 2018-10-15